Comparison of responder rates between anamorelin and placebo by baseline characteristics of patients
cancer, appetite
ONCOLOGY, CANCER
The results of the responder analysis of LBM, body weight, and appetite are shown in Figure Subgroup analysis of LBM (A), body weight (B), and appetite (QOL‐ACD item 8; C) responder rates according to sex, age, Alb, albumin; BMI, BW loss within 6 months, CRP, C‐reactive protein; ECOG PS, and concomitant anticancer therapy. BMI, body mass index; BW, body weight; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR‐TKI, epidermal growth factor receptor tyrosine kinase inhibitor; LBM, lean body weight; OR, odds ratio; QOL‐ACD, quality of life questionnaire for cancer patients treated with anticancer drugs.